

# Zackery P Bulman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4979521/publications.pdf>

Version: 2024-02-01

38  
papers

797  
citations

516710

16  
h-index

552781

26  
g-index

39  
all docs

39  
docs citations

39  
times ranked

1046  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inoculum effect of $\beta$ -lactam antibiotics. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2825-2843.	3.0	83
2	High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant <i>Acinetobacter baumannii</i> in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	60
3	Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use. <i>Pharmacotherapy</i> , 2015, 35, 34-42.	2.6	52
4	Polymyxin Combinations Combat <i>Escherichia coli</i> Harboring <i>mcr-1</i> and <i>bla</i> <sub>NDM-5</sub> : Preparation for a Postantibiotic Era. <i>MBio</i> , 2017, 8, .	4.1	50
5	Multidrug Resistant <i>Acinetobacter baumannii</i> : Resistance by Any Other Name Would Still be Hard to Treat. <i>Current Infectious Disease Reports</i> , 2019, 21, 46.	3.0	47
6	Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria. <i>Infectious Diseases and Therapy</i> , 2015, 4, 391-415.	4.0	45
7	Therapeutic Options for Metallo- $\beta$ -Lactamase-Producing Enterobacterales. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 125-142.	2.7	45
8	Pharmacodynamics of colistin and fosfomycin: a "treasure trove" combination combats KPC-producing <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1985-1990.	3.0	43
9	A novel property of propolis (bee glue): Anti-pathogenic activity by inhibition of N-acyl-homoserine lactone mediated signaling in bacteria. <i>Journal of Ethnopharmacology</i> , 2011, 138, 788-797.	4.1	29
10	Evolution of <i>Staphylococcus aureus</i> under Vancomycin Selective Pressure: the Role of the Small-Colony Variant Phenotype. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1347-1351.	3.2	26
11	Genomic Features Associated with the Degree of Phenotypic Resistance to Carbapenems in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> . <i>MSystems</i> , 2021, 6, e0019421.	3.8	26
12	A combination of ceftaroline and daptomycin has synergistic and bactericidal activity <i>in vitro</i> against daptomycin nonsusceptible methicillin-resistant <i>Staphylococcus aureus</i> (MRSA). <i>Infectious Diseases</i> , 2017, 49, 410-416.	2.8	23
13	Rational Combinations of Polymyxins with Other Antibiotics. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1145, 251-288.	1.6	21
14	Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant <i>Stenotrophomonas maltophilia</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	21
15	Shifting Gears: The Future of Polymyxin Antibiotics. <i>Antibiotics</i> , 2019, 8, 42.	3.7	20
16	Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2870-2880.	3.2	18
17	Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in <i>Staphylococcus aureus</i> : Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1584-1591.	3.2	18
18	Research priorities towards precision antibiotic therapy to improve patient care. <i>Lancet Microbe</i> , The, 2022, 3, e795-e802.	7.3	17

#	ARTICLE	IF	CITATIONS
19	New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	14
20	Pharmacodynamics of dose-escalated "front-loading" polymyxin B regimens against polymyxin-resistant mcr-1-harboring <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2297-2303.	3.0	14
21	Influence of <i>rhlR</i> and <i>lasR</i> on Polymyxin Pharmacodynamics in <i>Pseudomonas aeruginosa</i> and Implications for Quorum Sensing Inhibition with Azithromycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	13
22	Aminoglycoside-resistance gene signatures are predictive of aminoglycoside MICs for carbapenem-resistant <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 356-363.	3.0	12
23	Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined $\beta$ -Lactamase-Producing <i>Escherichia coli</i> : Insights into the Pharmacokinetics/Pharmacodynamics of $\beta$ -Lactamase Inhibitor Combinations. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1967-1973.	3.2	11
24	Unraveling the Gentamicin Drug Product Complexity Reveals Variation in Microbiological Activities and Nephrotoxicity. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	10
25	Successful cure of daptomycin-non-susceptible, vancomycin-intermediate <i>Staphylococcus aureus</i> prosthetic aortic valve endocarditis directed by synergistic <i>in vitro</i> time-kill study. <i>Infectious Diseases</i> , 2019, 51, 287-292.	2.8	9
26	Optimizing aminoglycoside selection for KPC-producing <i>Klebsiella pneumoniae</i> with the aminoglycoside-modifying enzyme (AME) gene <i>aac(6)-Ib</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 671-679.	3.0	9
27	Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0069221.	3.2	9
28	<i>In vitro</i> pharmacodynamic evaluation of ceftolozane/tazobactam against $\beta$ -lactamase-producing <i>Escherichia coli</i> in a hollow-fibre infection model. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 25-30.	2.5	8
29	Antibiotic susceptibility patterns of viridans group streptococci isolates in the United States from 2010 to 2020. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, .	2.1	7
30	Native valve <i>Proteus mirabilis</i> endocarditis: successful treatment of a rare entity formulated by <i>in vitro</i> synergy antibiotic testing. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016215956.	0.5	6
31	Emergence of Polymyxin B Resistance Influences Pathogenicity in <i>Pseudomonas aeruginosa</i> Mutators. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4343-4346.	3.2	5
32	Polymyxin B and fosfomycin thwart KPC-producing <i>Klebsiella pneumoniae</i> in the hollow-fibre infection model. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 114-118.	2.5	5
33	<i>In Vitro</i> Pharmacodynamic Analyses Help Guide the Treatment of Multidrug-Resistant <i>Enterococcus faecium</i> and Carbapenem-Resistant <i>Enterobacter cloacae</i> Bacteremia in a Liver Transplant Patient. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz545.	0.9	5
34	Combatting Planktonic and Biofilm Populations of Carbapenem-Resistant <i>Acinetobacter baumannii</i> with Polymyxin-Based Combinations. <i>Antibiotics</i> , 2022, 11, 959.	3.7	5
35	<i>In vitro</i> Optimization of Ceftazidime/Avibactam for KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Frontiers in Microbiology</i> , 2021, 12, 618087.	3.5	4
36	A coup d'État by NDM-producing <i>Klebsiella pneumoniae</i> overthrows the major bacterial population during KPC-directed therapy. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 98, 115080.	1.8	3

#	ARTICLE	IF	CITATIONS
37	Capability of <i>Enterococcus faecalis</i> to shield Gram-negative pathogens from aminoglycoside exposure. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2610-2614.	3.0	3
38	Ceftazidime-avibactam based combinations against carbapenemase producing <i>Klebsiella pneumoniae</i> harboring hypervirulence plasmids. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 3946-3954.	4.1	1